Magnetic field induced inhibition of human osteosarcoma cells treated with adriamycin

Cancer Biochemistry Biophysics

Volumn 17, Issue 1-2, 1999, Pages 89-98

  Chakkalakal, D A ^a   Mollner, T J ^a   Bogard, M R ^a   Fritz, E D ^a   Novak, J R ^a   Mcguire, M H ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adriamycin; Cell proliferation; Chemotherapy; Human osteosarcoma cells; Magnetic field

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN;

ARTICLE; BONE TUMOR; CELL CULTURE; CELL DIVISION; DOSE RESPONSE; DRUG EFFECT; ELECTROMAGNETIC FIELD; HUMAN; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; PATHOLOGY;

ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; CELL DIVISION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ELECTROMAGNETIC FIELDS; HUMANS; OSTEOSARCOMA; TUMOR CELLS, CULTURED;

EID: 0032826847     PISSN: 03057232     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 2 phase arrest by different antitumor agents. Europ. J. Cancer 14, 741-745.
2. Bell, D. F., R.S. Bell, H.J. Mankin, M.C. Gebhardt, F. Weltie and T O'Brien (1988). Kinetic effects of adriamycin and bleomycin on two osteosarcoma models. J. Orthop. Res. 6, 51-57
3. Cadossi, R. and P. Zucchini, G. Emilia, C. Franceschi, A. Cossarizza, M. Santantonio, G. Mandolini and G. Torelli (1991). Effect of low frequency low energy pulsing electro-magnetic fields on mice injected with cyclophosphamide. Exp. Hematol. 19, 196-201.
4. Friedman, M. A. and S.K. Carter (1972). The therapy of osteogenic sarcoma: current status and thoughts for the future. J. Surg. Oncol. 4, 482.
5. Gebhardt, M. C., K. Kusuzaki, H.J. Mankin and D.S. Springfield (1994). An assay to measure adriamycin binding in osteosarcoma cells. J. Orthop Res. 12, 621-627.
6. Haberkorn, U., F. Obwerdorfer, T. Klenner, L.G. Strauss, M. Stohr, R. Wallich, A Altmann, and G. Van Kaick (1994). Metabolic and transcriptional changes in osteosarcoma cells treated with chemotherapeutic drugs. Nucl. Med. Biol. 21, 835-845.
7. Hannan, Jr. C. J., Y. Liang, J.D. Allison and J.R. Searle (1994). In vitro cytotoxicity against human cancer cell lines during pulsed magnetic field exposure. Anticancer Res. 14, 1517-1520.
8. Hudson, M. M.R. Jaffe, N. Jaffe, A Ayala, A.K. Raymond, H. Carrasco, S. Wallace, J. Murray and R. Robertson (1990). Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J. Clin. Oncol. 8, 1988-1997.
9. Link, M. P. (1993). Preoperative and adjuvant chemotherapy in osteosarcoma In J.F. Novak and J.H. McMaster (Eds.), Frontiers of Osteosarcoma Research: Interdisciplinary Survey of Clinical and Research Advances, Seattle, Hogrefe and Huber. pp. 41-49.
10. Link, M. P, A.M Goorin, M. Horowitz, W.H. Meyer, J. Belasco, A. Baker, A. Ayala and J. Shuster (1991). Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Clin. Orthop. 270, 814.
11. Luben, R.A (1991). The effects of low-energy electromagnetic fields (pulsed and DC) on membrane signal transduction processes in biological systems. Health Phys. 61, 15-28.
12. Misakian, M., A.R. Sheppard, D. Krause, M.E. Frazier and D.L Miller (1993). Biological, physical, and electrical parameters for in vitro studies with ELF magnetic and electric fields: a primer. Bioelectromagnetics Suppl. 2, 1-73.
13. Omote, Y., M Hosokawa, M. Komatsumoto, T. Namieno, S. Nakajima, Y. Kubo and H. Kobayashi (1990). Treatment of experimental tumors with a combination of a pulsing magnetic field and an antitumor drug. Jpn. J. Cancer Res. 8, 956-961.
14. Rosen, G., B. Caparros, A.G. Huvos, C. Kosloff, A. Nirenberg, A. Cacavio, R.C. Marcove, J.M. Lane, B. Mehta and B Urban (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 4, 1221-1230.
15. 2. Nature 254, 245-247.
16. Tobey, R. A., H A. Crissman and M.S. Oka (1976). Arrested and cycling CHO cells as a kinetic model, studies with adriamycin. Cancer Treat. Rep. 60, 1829-1837.
17. Tritton, T. R. and G. Yee (1982). The anticancer agent adnamycin can be actively cytotoxic without entering cells. Science 217, 248-250.